Therapeutic prospects of mesenchymal stem/stromal cells in COVID-19 associated pulmonary diseases: From bench to bedside

被引：11

作者：

Zhang, Lei-Sheng ^{[1
,2
,3
,4
,5
,6
,7
]}

Yu, Yi ^{[3
,4
,5
,8
]}

Yu, Hao ^{[6
,9
,10
,11
]}

Han, Zhong-Chao ^{[3
,4
,5
,7
,9
,10
,11
]}

机构：

[1] Shandong First Med Univ, Qianfoshan Hosp, Jinan 250014, Shandong, Peoples R China

[2] Shandong First Med Univ, Affiliated Hosp 1, Jinan 250014, Shandong, Peoples R China

[3] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Tianjin 300020, Peoples R China

[4] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Blood Dis, Inst Hematol, Tianjin 300020, Peoples R China

[5] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Tianjin 300020, Peoples R China

[6] Nankai Univ, Sch Med, 94 Weijin Rd, Tianjin 300071, Peoples R China

[7] Health Biotech Tianjin Stem Cell Res Inst Co Ltd, Precis Med Div, Tianjin 301700, Peoples R China

[8] Zhejiang Univ, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China

[9] Cell Prod Natl Engn Ctr, Tianjin 300457, Peoples R China

[10] Natl Stem Cell Engn Res Ctr, Tianjin 300457, Peoples R China

[11] Tianjin IMCELL Stem Cell & Gene Technol Co Ltd, Tianjin 300457, Peoples R China

来源：

WORLD JOURNAL OF STEM CELLS | 2021年 / 13卷 / 08期

基金：

中国国家自然科学基金; 中国博士后科学基金;

关键词：

Mesenchymal stem/stromal cells; COVID-19; Acute lung injury; cute res-piratory distress syndrome; Pulmonary fibrosis; Molecular mechanism; ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME; STEM-CELLS; BONE-MARROW; STROMAL CELLS; II CELLS; MICROVESICLES; PNEUMONIA; FIBROSIS; ENGRAFTMENT;

D O I：

10.4252/wjsc.v13.i8.1058

中图分类号：

Q813 [细胞工程];

学科分类号：

摘要：

The ongoing outbreak of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 has become a sudden public emergency of international concern and seriously threatens millions of people's life health. Two current studies have indicated a favorable role for mesenchymal stem/stromal cells (MSCs) in clinical remission of COVID-19 associated pulmonary diseases, yet the systematical elaboration of the therapeutics and underlying mechanism is far from satisfaction. In the present review, we summarize the therapeutic potential of MSCs in COVID-19 associated pulmonary diseases such as pneumonia induced acute lung injury, acute respiratory distress syndrome, and pulmonary fibrosis. Furthermore, we review the underlying mechanism of MSCs including direct- and trans-differentiation, autocrine and paracrine anti-inflammatory effects, homing, and neovascularization, as well as constitutive microenvironment. Finally, we discuss the prospects and supervision of MSC-based cytotherapy for COVID-19 management before large-scale application in clinical practice. Collectively, this review supplies overwhelming new references for understanding the landscapes of MSCs in the remission of COVID-19 associated pulmonary diseases.

引用

页码：1058 / 1071

页数：14

共 90 条

[1] Vascular endothelial growth factor mediates the therapeutic efficacy of mesenchymal stem cell-derived extracellular vesicles against neonatal hyperoxic lung injury [J].